Literature DB >> 35675600

Care Levels for Fetal Therapy Centers.

Ahmet A Baschat1, Sean B Blackwell, Debnath Chatterjee, James J Cummings, Stephen P Emery, Shinjiro Hirose, Lisa M Hollier, Anthony Johnson, Sarah J Kilpatrick, Francois I Luks, M Kathryn Menard, Lawrence B McCullough, Julie S Moldenhauer, Anita J Moon-Grady, George B Mychaliska, Michael Narvey, Mary E Norton, Mark D Rollins, Eric D Skarsgard, KuoJen Tsao, Barbara B Warner, Abigail Wilpers, Greg Ryan.   

Abstract

Fetal therapies undertaken to improve fetal outcome or to optimize transition to neonate life often entail some level of maternal, fetal, or neonatal risk. A fetal therapy center needs access to resources to carry out such therapies and to manage maternal, fetal, and neonatal complications that might arise, either related to the therapy per se or as part of the underlying fetal or maternal condition. Accordingly, a fetal therapy center requires a dedicated operational infrastructure and necessary resources to allow for appropriate oversight and monitoring of clinical performance and to facilitate multidisciplinary collaboration between the relevant specialties. Three care levels for fetal therapy centers are proposed to match the anticipated care complexity, with appropriate resources to achieve an optimal outcome at an institutional and regional level. A level I fetal therapy center should be capable of offering fetal interventions that may be associated with obstetric risks of preterm birth or membrane rupture but that would be very unlikely to require maternal medical subspecialty or intensive care, with neonatal risks not exceeding those of moderate prematurity. A level II center should have the incremental capacity to provide maternal intensive care and to manage extreme neonatal prematurity. A level III therapy center should offer the full range of fetal interventions (including open fetal surgery) and be able manage any of the associated maternal complications and comorbidities, as well as have access to neonatal and pediatric surgical intervention including indicated surgery for neonates with congenital anomalies.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 35675600      PMCID: PMC9202072          DOI: 10.1097/AOG.0000000000004793

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.623


  126 in total

1.  Monopolar thermocoagulation in acardiac twinning.

Authors:  A Holmes; E Jauniaux; C Rodeck
Journal:  BJOG       Date:  2001-09       Impact factor: 6.531

2.  The accreditation of ultrasound practices: impact on compliance with minimum performance guidelines.

Authors:  Alfred Z Abuhamad; Beryl R Benacerraf; Paula Woletz; Bonnie L Burke
Journal:  J Ultrasound Med       Date:  2004-08       Impact factor: 2.153

3.  When are amniotic fluid viral PCR studies indicated in prenatal diagnosis?

Authors:  L L Adams; S Gungor; S Turan; J N Kopelman; C R Harman; A A Baschat
Journal:  Prenat Diagn       Date:  2012-01-24       Impact factor: 3.050

4.  Informed Consent and Shared Decision Making in Obstetrics and Gynecology: ACOG Committee Opinion, Number 819.

Authors: 
Journal:  Obstet Gynecol       Date:  2021-02-01       Impact factor: 7.661

5.  Committee opinion no. 501: Maternal-fetal intervention and fetal care centers.

Authors: 
Journal:  Obstet Gynecol       Date:  2011-08       Impact factor: 7.661

Review 6.  Fetal primary pleural effusions: Prenatal diagnosis and management.

Authors:  Nimrah Abbasi; Greg Ryan
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2019-01-12       Impact factor: 5.237

7.  Fetal treatment 1982.

Authors:  M R Harrison; R A Filly; M S Golbus; R L Berkowitz; P W Callen; T G Canty; C Catz; W H Clewell; R Depp; M S Edwards; J C Fletcher; F D Frigoletto; W J Garrett; M L Johnson; A Jonsen; A A De Lorimier; W A Liley; M J Mahoney; F D Manning; P R Meier; M Michejda; D K Nakayama; L Nelson; J B Newkirk; K Pringle; C Rodeck; M A Rosen; J D Schulman
Journal:  N Engl J Med       Date:  1982-12-23       Impact factor: 91.245

8.  Core outcome set for research studies evaluating treatments for twin-twin transfusion syndrome.

Authors:  H Perry; J M N Duffy; K Reed; A Baschat; J Deprest; K Hecher; L Lewi; E Lopriore; D Oepkes; A Khalil
Journal:  Ultrasound Obstet Gynecol       Date:  2019-07-11       Impact factor: 7.299

9.  Fetal tachyarrhythmias: transplacental and direct treatment of the fetus-a report of 60 cases.

Authors:  M Hansmann; U Gembruch; R Bald; M Manz; D A Redel
Journal:  Ultrasound Obstet Gynecol       Date:  1991-05-01       Impact factor: 7.299

10.  Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung.

Authors:  Timothy M Crombleholme; Beverly Coleman; Holly Hedrick; Kenneth Liechty; Lori Howell; Alan W Flake; Mark Johnson; N Scott Adzick
Journal:  J Pediatr Surg       Date:  2002-03       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.